JENA, Germany, Aug. 07, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced its financial results for the three months ended June 30, 2025, and provided a business update.
Related Questions
Did the company disclose any changes in its capital structure, such as share issuances, debt financing, or stock option exercises?
What is the current cash runway and does the company have sufficient liquidity to meet its operating needs?
Are there any new partnership, licensing, or collaboration agreements announced that could affect future cash inflows?
Did the company provide any updated guidance or outlook for Q3 2025 and the full year 2025?
How did InflaRx's Q2 2025 revenue and net loss compare to consensus estimates?
What are the key milestones or upcoming data readouts for its complement system therapeutics that could drive the stock?
What is the status of any regulatory submissions (e.g., IND, NDA, or EMA filings) and expected timelines?
How does the progress of InflaRx's pipeline compare to its main competitors in the anti‑inflammatory space?
What are the potential upside or downside risks highlighted in the management discussion that could impact the stock price?
How might the recent business update influence analyst sentiment and target price revisions for IFRX?